Memantine: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
<StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/963765/Cv/1'> | <StructureSection load='' size='340' side='right' caption='Caption for this structure' scene='96/963765/Cv/1'> | ||
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. | Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [[https://en.wikipedia.org/wiki/Memantine]]. | ||
</StructureSection> | </StructureSection> | ||
== References == | == References == | ||
<references/> | <references/> | ||
Revision as of 12:08, 30 April 2023
Memantine is a medication used to slow the progression of moderate-to-severe Alzheimer's disease. It is believed to work by acting on NMDA receptors, working as pore blockers of these ion channels. See also [[1]].
|
| ||||||||||